Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mohannad B. Bisharat"'
Autor:
Rashad H. Khazi Syed, Vikram S. Nijjar, Mohi E. Alkadri, John C. Moscona, Matthew N. Peters, Morgan J. Katz, Patrice Delafontaine, Anand Irimpen, Mohannad B. Bisharat, Thomas A. Turnage
Publikováno v:
The American Journal of Cardiology. 111:800-803
The onset of acute myocardial infarction (AMI) has been shown to occur in a nonrandom pattern, with peaks in midmorning and on weekdays (especially Monday). The incidence of AMI has been shown to increase locally after natural disasters, but the effe
Autor:
Mohannad B. Bisharat, Kathleen S. Hesterman, Morgan J. Katz, Meredith B. Barnes, Ryan R. Brown, Anand Irimpen, Matthew N. Peters, Vikram S. Nijjar
Publikováno v:
Baylor University Medical Center Proceedings. 26:35-38
Although commonly fatal, bacterial pericarditis is often not diagnosed antemortem due to its infrequent occurrence and fulminant course. Historically, Streptococcus pneumoniae has been the most common cause of bacterial pericarditis. Over the past 70
Autor:
Morgan J. Katz, Mohannad B. Bisharat, John C. Moscona, Drew Baldwin, Matthew Peters, Christopher D. Press, Rashad H. Khazi Syed, Vikram S. Nijjar
Publikováno v:
Baylor University Medical Center Proceedings. 25:231-233
May-Thurner syndrome is a rarely diagnosed condition in which patients develop iliofemoral deep venous thrombosis (DVT) due to an anatomical variant in which the right common iliac artery overlies and compresses the left common iliac vein against the
Autor:
Morgan J. Katz, Mohannad B. Bisharat, Patrice Delafontaine, Thomas A. Turnage, Anand Irimpen, John C. Moscona, Matthew N. Peters, Rashad H. Khazi Syed, Mohi E. Alkadri, Vikram S. Nijjar
Publikováno v:
Journal of the American College of Cardiology. 61(10)
Autor:
Mohannad B. Bisharat, Christopher D. Press, Morgan J. Katz, Asif H. Anwar, Rashad H. Khazi Syed, Matthew N. Peters, John C. Moscona, Vikram S. Nijjar, Alison A. Egan
Publikováno v:
Proceedings (Baylor University. Medical Center). 25(4)
Glycoprotein (GP) IIb/IIIa receptor antagonists are powerful antiplatelet agents that are typically used in percutaneous coronary intervention. All three GP IIb/IIIa agents currently approved for use in the United States cause thrombocytopenia as a r
Publikováno v:
Chest. 132:541C